Luciana Preger: Leading Gilead's Global Efforts in Oncology Innovation and Patient Care
Luciana Preger attributes her early exposure to her father's medical career as a significant influence on her own path in medicine. Now a physician with over two decades of experience in the pharmaceutical industry, she joined Gilead to advance cancer treatments.
"Accompanying my father on hospital rounds in Rio de Janeiro during my childhood, I was deeply moved by the connections he made with patients," recalls Luciana, who is the Vice President of Global Medical Affairs in Oncology. "The emotions I witnessed during those times have stayed with me, and I strive never to forget them."
Her work is driven by a commitment to improving patient outcomes and expanding access to medicine. Luciana was drawn to Gilead because of its legacy of increasing global access to transformative medicines, hoping to play a significant role in bridging the gap between scientific innovation and patient care.
“To truly transform cancer treatment, we must base oncology advancements on equitable care,” she states. “Scientific innovation is meaningless without clear access, and ensuring access to care is central to all our efforts at Gilead.”
Luciana’s career has spanned Brazil, France, and the U.S. Seeking to make a substantial impact in oncology, she saw a unique opportunity in Silicon Valley to work with leading experts in cancer research and treatment.
Before joining Gilead, Luciana contributed to the development of over 10 oncology therapies, many of which have demonstrated survival benefits in various cancers. Currently, she is enthusiastic about Gilead’s expanding oncology portfolio, which has reached over 30,000 patients and continues to explore its impact on challenging tumor types.
In her role, she guides the strategic direction of Global Medical Affairs initiatives in oncology, advancing the scientific understanding of Gilead’s therapies. Her team facilitates the dissemination of clinical data, collaborates with key opinion leaders, supports external research, and develops educational programs to inform clinical practices.
Luciana is proud to be part of a company dedicated to addressing the needs of those requiring its medicines the most. “Our work is significant. We contribute to prolonging lives and addressing the unmet needs of cancer patients worldwide,” she says. “Ultimately, we aim to achieve a cure and restore hope in the face of cancer.”
"Accompanying my father on hospital rounds in Rio de Janeiro during my childhood, I was deeply moved by the connections he made with patients," recalls Luciana, who is the Vice President of Global Medical Affairs in Oncology. "The emotions I witnessed during those times have stayed with me, and I strive never to forget them."
Her work is driven by a commitment to improving patient outcomes and expanding access to medicine. Luciana was drawn to Gilead because of its legacy of increasing global access to transformative medicines, hoping to play a significant role in bridging the gap between scientific innovation and patient care.
“To truly transform cancer treatment, we must base oncology advancements on equitable care,” she states. “Scientific innovation is meaningless without clear access, and ensuring access to care is central to all our efforts at Gilead.”
Luciana’s career has spanned Brazil, France, and the U.S. Seeking to make a substantial impact in oncology, she saw a unique opportunity in Silicon Valley to work with leading experts in cancer research and treatment.
Before joining Gilead, Luciana contributed to the development of over 10 oncology therapies, many of which have demonstrated survival benefits in various cancers. Currently, she is enthusiastic about Gilead’s expanding oncology portfolio, which has reached over 30,000 patients and continues to explore its impact on challenging tumor types.
In her role, she guides the strategic direction of Global Medical Affairs initiatives in oncology, advancing the scientific understanding of Gilead’s therapies. Her team facilitates the dissemination of clinical data, collaborates with key opinion leaders, supports external research, and develops educational programs to inform clinical practices.
Luciana is proud to be part of a company dedicated to addressing the needs of those requiring its medicines the most. “Our work is significant. We contribute to prolonging lives and addressing the unmet needs of cancer patients worldwide,” she says. “Ultimately, we aim to achieve a cure and restore hope in the face of cancer.”
Companies